The large-scale DYNAGITO study will examine the potential benefit of tiotropium + olodaterol Respimat FDC† compared to Spiriva (tiotropium) Respimat on COPD symptoms.

 Lead study investigator Peter Calverley, Professor of Pulmonary and Rehabilitation Medicine, University of Liverpool, UK commented, “Exacerbations not only worsen the lung function of COPD patients and often lead to hospitalisation, they also have a significant impact on patients’ overall wellbeing. In severe cases, exacerbations even increase the risk of death. Therefore, there is an ongoing need to optimise the effect of treatment in reducing the risk of exacerbations in COPD.”

View the full story at